Our Cell Therapies
We are committed to developing transformative cell therapies to improve outcomes for patients
Our Cell Therapies
We are committed to developing transformative cell therapies to improve outcomes for patients
Cell Therapy
Our body’s immune system can recognize cancer cells as abnormal and kill them. However, this process can fail to get rid of cancer cells entirely. Immunotherapy is a treatment for some types of cancer that helps the body’s immune system find and kill cancer cells.
Autologous T-cell therapy is a highly personalized immunotherapy that involves taking cells from the patient, improving their functionality and transferring them back to the patient. By reprogramming the T cells, they can be designed with the potential to address a wide range of diseases, including cancer. Unlike other cancer therapies that might require ongoing treatments, cell therapies often offer a one-time treatment option.
Steps Involved in Treatment with a Cell Therapy
Cell or tissue collection
Manufacturing
(cell reprograming and expansion)
Lymphodepletion
(preparing the body for treatment)
Single dose of cell therapy
Post-treatment monitoring
Why was Lyell founded with a focus on solid tumors?
90% of cancers are solid tumors. Yet, cell therapies have shown limited success in treating solid tumors. Our goal is to change this. Our T-cell reprogramming technologies are designed to address efficacy barriers to cell therapy in solid tumors.
Learn MoreLearn more about Lyell's approach and capabilities to tackling solid tumors with cell therapy.
At Lyell, we are applying our technology to reprogram chimeric antigen receptor (CAR) T cells to resist exhaustion and remain potent. CAR T cells are cells that are modified to recognize and kill cancer cells that have specific biomarkers or antigens (types of proteins) on their cell surface.
We use two different and complementary types of reprogramming technologies that are designed to make our cell therapy product candidates more potent and longer lasting to fight solid tumors.
Genetic Reprogramming, which includes our c-Jun overexpression and NR4A3 knockout technologies, aims to delay exhaustion and create more potent T cells with enhanced and long-lasting cancer-fighting ability
Epigenetic Reprogramming, which includes our Epi-R™ manufacturing protocol and Stim-R™ technology, aims to enhance qualities of stemness, persistence and function of T cells to drive potent and long-lasting cancer cell killing
Our Product Candidates
Clinical Trials
The participation of patients and their families in clinical trials enables us to evaluate our investigational product candidates for safety and efficacy. We are driven to defeat cancers and are grateful for those who choose to join us on this journey.
Click the disease areas below to learn more about how we are advancing next-generation CAR T-cells therapies for the potential treatment of solid tumors and hematologic malignancies.
Disease facts:
- One of the leading causes of cancer deaths among women
- Only about 20% of ovarian cancers are diagnosed at an early stage
LYL119
- Next-generation investigational CAR T-cell therapy incorporating additional anti-exhaustion technology designed for improved potency
- Targets ROR1, a protein expressed in various cancers, including ovarian cancer
Clinical Trial
Stage: Phase 1 trial to evaluate the safety and tolerability of LYL119 in patients with ROR1+ relapsed or refractory platinum-resistant ovarian cancer or endometrial cancer, with subsequent expansion into other tumor types including NSCLC and TNBC
More info: Email clinicaltrialslyell.com
Disease facts:
- The most prevalent gynecological cancer and the sixth most common malignancy worldwide
- Increasing incidence over the last decade and one of the few cancers with increasing mortality
LYL119
- Next-generation investigational CAR T-cell therapy incorporating additional anti-exhaustion technology designed for improved potency
- Targets ROR1, a protein expressed in various cancers, including endometrial cancer
Clinical Trial
Stage: Phase 1 trial to evaluate the safety and tolerability of LYL119 in patients with ROR1+ relapsed or refractory platinum-resistant ovarian cancer or endometrial cancer, with subsequent expansion into other tumor types including NSCLC and TNBC
More info: Email clinicaltrialslyell.com
Disease facts:
- Non-Hodgkin lymphoma (NHL) is a common cancer. It is estimated that approximately 81,000 people in the United States will be diagnosed with NHL in 2024
- B-cell lymphoma is the most common type of NHL, comprising approximately 85% of all lymphomas in the United States.
IMPT-314
- Next-generation dual-targeting CD19/CD20 investigational CAR T-cell therapy designed for improved durability
- Targets CD19 and CD20, two proteins present on B-cell lymphoma
Clinical Trial
More info: Email clinicaltrialslyell.com